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Abstract: High-fructose intake in healthy men is associated with characteristics of metabolic
syndrome. Extensive knowledge exists about the differences between hepatic fructose and glucose
metabolism and fructose-specific mechanisms favoring the development of metabolic disturbances.
Nevertheless, the causal relationship between fructose consumption and metabolic alterations is still
debated. Multiple effects of fructose on hepatic metabolism are attributed to the fact that the liver
represents the major sink of fructose. Fructose, as a lipogenic substrate and potent inducer of lipogenic
enzyme expression, enhances fatty acid synthesis. Consequently, increased hepatic diacylglycerols
(DAG) are thought to directly interfere with insulin signaling. However, independently of this effect,
fructose may also counteract insulin-mediated effects on liver metabolism by a range of mechanisms.
It may drive gluconeogenesis not only as a gluconeogenic substrate, but also as a potent inducer
of carbohydrate responsive element binding protein (ChREBP), which induces the expression of
lipogenic enzymes as well as gluconeogenic enzymes. It remains a challenge to determine the relative
contributions of the impact of fructose on hepatic transcriptome, proteome and allosterome changes
and consequently on the regulation of plasma glucose metabolism/homeostasis. Mathematical
models exist modeling hepatic glucose metabolism. Future models should not only consider the
hepatic adjustments of enzyme abundances and activities in response to changing plasma glucose
and insulin/glucagon concentrations, but also to varying fructose concentrations for defining the
role of fructose in the hepatic control of plasma glucose homeostasis.
Keywords: NAFLD; type 2 diabetes; fructose; glucose; insulin; ChREBP; SREBP1c; gluconeogenesis;
de novo lipogenesis; triglyceride
1. Introduction
Eating habits and lifestyle are subject to change and are determined by socio-economic factors.
In modern societies, the surplus offer of food leads to an excess caloric intake that may go along
with reduced physical activity. The consequences are obesity with associated health risks such as
nonalcoholic fatty liver disease (NAFLD) or type 2 diabetes. The continuously increased fructose
consumption as sucrose and high fructose corn syrup over the past decades coincides with the raised
prevalence of obesity, NAFLD, and type 2 diabetes [1–3]. These diseases in the end may lead to
severe comorbidities as liver fibrosis/cirrhosis and consecutive failure of liver function (in the case
of NAFLD), or severe cardiovascular disease as well as kidney, eye, and neurological disease in the
case of diabetes. This coincidence led to a wide debate about the potential health risks of fructose
consumption. It is beyond debate that the consumption of food, and especially beverages rich in
fructose content, is often associated with an excessive energy intake. However, it is still an open
question whether fructose exerts a negative effect on metabolism independently from effects on body
weight in an energy balanced diet [4–6].
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Studies about different forms of nutrition point out the importance of a food mix adjusted to our
metabolic/biochemical disposition. During evolution, the human metabolism became adapted to gain
energy from different sources for survival in an environment with a seasonally changing food offer.
It is prepared to gain energy from a variety of simple and complex carbohydrates (consisting of a
range of sugar types) as well as from fatty acids. The organism provides cellular pathways to obtain
flexibility in the use of various energy carriers. However, may an unbalanced diet stretch cellular
regulatory mechanisms to their limits and eventually impair health? What is the optimal mix of energy
carriers for the human organism in terms of type of carbohydrates and fat for preserving health? There
is no widely accepted paradigm in this respect.
The liver, as a central organ in carbohydrate metabolism, serves as an energy hub. It represents a
major sink for carbohydrates. Hepatic glucose uptake contributes to the restoration of blood glucose
homeostasis after a meal. Carbohydrates are stored as glycogen or converted into fatty acids which
are then released into the plasma and deposited in adipose tissue. During fasting, glucose from
the breakdown of glycogen, and gluconeogenesis is released by the liver maintaining blood glucose
homeostasis. Impairment of such essential hepatic functions manifests as disturbed insulin sensitivity,
increased hepatic glucose production and de novo lipogenesis.
This article aims at highlighting the role of different types of sugars and their potential specific
adverse effects on the liver. We refer to data from animal studies that examined diet induced gene
expression and underlying molecular mechanisms, but we also included data from nutritional human
studies investigating metabolic outcome based on tracer methods. We focus on the interconnections of
fructose and glucose metabolism.
2. Absorption and Distribution of Hexoses
Prior to going into the details of liver lipid metabolism and its adaptation to carbohydrate rich
diets, some general differences between glucose and fructose and their potential roles as competitors
need to be pointed out.
It cannot be stressed enough that the cellular absorption and distribution of glucose and fructose
differ markedly. Only two transporters, namely GLUT2 and GLUT5, of the 14 members of the glucose
transporter (GLUT) family are permeable for fructose [7,8]. They are responsible for fructose uptake
by facilitated diffusion. GLUT2 transporter is expressed in intestinal and kidney epithelial cells,
on pancreatic beta cells, and hepatocytes [9]. In pancreatic beta cells, increased blood glucose levels
induce insulin secretion. GLUT2 has also been attributed to a glucose sensing role on brain cells [10].
GLUT5 has an exclusive specificity for fructose [11,12]. Its main expression site is the apical membrane
of intestinal epithelial cells providing a major route for absorption of dietary fructose [11,13,14].
GLUT5 expression is induced during the postnatal development. Its expression is dramatically
stimulated by the introduction of dietary fructose and it seems to be modulated by paracrine and
endocrine signals leading to a diurnal variation of expression in adults [15–18]. Fructose enters the
epithelial intestinal cells via the GLUT5 transporter by the mechanism of facilitated diffusion, whereas
glucose enters the enterocytes via sodium-glucose-cotransporter 1, an active transporter [13,19].
Further, GLUT2 may contribute to intestinal fructose and glucose absorption, although this is to
a minor extent [20–23]. In intestinal cells, a proportion of fructose is supposed to be converted
into glucose as enzymes of the gluconeogenetic pathways are induced by intestinal fructose [24].
Fructose and glucose are released into the portal vein via GLUT2 that is located in the basolateral
membrane of enterocytes. Consecutively, a large proportion of fructose is taken up postprandially by
the liver representing its major sink [25]. However, skeletal muscle, adipose tissue, and the kidney also
contribute to fructose clearance from the blood [26–29]. Glucose is distributed into different tissues
according to the wide expression of different glucose transporters expressed by most mammalian
cells [7]. Most important for postprandial whole body glucose disposal are muscle cells that take up
glucose via GLUT 4, which is upregulated by insulin [30].
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Hepatic uptake of both glucose and fructose is mediated by the GLUT2 transporter, which is
constitutively expressed on hepatocytes and facilitates diffusion [9]. The affinity of GLUT2 for glucose
is higher than for fructose (Km for glucose is ~17 mM and for fructose ~76 mM) [31].
After hepatic uptake, fructose and glucose are phosphorylated by different kinases. In the liver,
fructose is phosphorylated by the high-activity keto-hexokinase isoform C (KHK-C), which is more
effective than the ubiquitous low-activity KHK-A, and subsequently rapidly converted into trioses [32].
The rapid processing of entering fructose is maintaining the fructose concentration gradient between
plasma and hepatocytes that leads to a continuous uptake of fructose into the hepatocyte [33,34].
The importance of KHK for the uptake of fructose is not only reflected by the fact that selective
knock-out of KHK-A isoform may enhance fructose influx to the liver, but also that a switch from the
KHK-A to the KHK-C isoform enhances fructose metabolism, whereas a switch from KHK-C to KHK-A
reduces fructose metabolism [35,36]. KHK is neither feedback-inhibited nor allosterically regulated [37].
In contrast, glucose is phosphorylated by glucokinase (GK), whose transcription is induced by
insulin and which is acutely regulated by GK regulatory protein (GKRP) [38–41]. GKRP’s inhibitory
effect on GK is increased by fructose-6-phosphate (F6P) and suppressed by fructose-1-phosphate
(F1P) [42–44]. Changes in GK activity due to genetic mutations are associated with a distinct form
of late onset diabetes characterized by impaired hepatic glucose disposal and increased glucose
production [45]. There is no direct allosteric feedback inhibition by glucose-6-phosphate (G6P) on
GK [46]. However, the allosteric activation of glycogen synthase (GS) by G6P may increase glucose
influx [47]. The phosphorylation rate by KHK is 10 times higher than by GK [48].
In summary, hepatic influx rates of fructose and glucose are determined by their plasma
concentrations and GLUT2 affinities, but also by the KHK activity for fructose and the GK and
GS activity for glucose.
3. How do Fructose and Glucose Modulate the Hepatic Uptake and Metabolism of Each Other?
The hepatic response to rising intracellular hexose concentrations is orchestrated by hormones, key
regulatory transcription factors, and metabolic intermediates that adjust both enzyme abundances and
activities. The relative importance of the regulation of enzyme abundances and activities, respectively,
in the control of the metabolic hexose flux and finally the restoration and maintenance of glucose
homeostasis is debated. However, the results from mathematical modeling suggest that the regulation
of enzyme abundances and of enzyme activities is equally important for the regulation of hepatic
hexose metabolism [49].
Certainly, a comparison of hepatic metabolism of glucose and fructose requires the consideration
of the diverse actions of insulin in order to identify possible sites of interaction of glucose and fructose
metabolism. We cover this issue by starting from the widely accepted actions of insulin on liver
metabolism namely blocking glycogenolysis and gluconeogenesis, stimulating glycogen synthesis and
thus regulating fasting glucose levels (illustrated in Figure 1) and aim to highlight fructose specific
effects that may enhance or antagonize the effects of insulin [50].
On one hand, insulin directly stimulates the expression of glycolytic enzymes such as GK,
phosphofructokinase 1 (PFK1), and pyruvate kinase (PK) and inhibits the expression of gluconeogenic
enzymes such as phosphoenolpyruvate carboxykinase (PEPCK), F-1,6-bisphosphatase (F1,6BPase), and
glucose-6-phosphatase (G6Pase). The regulatory mechanisms of gene expression by insulin involve
sterol regulatory element binding protein 1c (SREBP1c) and forkhead box O1 (FOXO1). On the other
hand, the immediate action of insulin is the regulation of enzyme activities namely of GS and citrate
lyase by changing their phosphorylation state.
Hepatic glucose metabolism is not only subject to insulin-dependent regulation, as a variety of
glucose intermediates as well as adenosine mono-phosphate (AMP), adenosine tri-phosphate (ATP),
and citrate are known to be potent direct or indirect modulators of glycolytic, gluconeogenic, and
glycogenic enzyme activities. Fructose specific intermediates also play an important role in the
regulatory system of glycolysis/gluconeogenesis and glycogenesis [33]. To be mentioned are the
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allosterically regulated glycolytic enzymes GK, PFK1, and the gluconeogenic enzymes F1,6BPase and
glycogenic enzymes GS (Figure 2).Nutrients 2017, 9, 1026  4 of 20 
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encoding glycolytic and  lipogenic enzymes  (green), but  inhibits  the expression of  those encoding 
gluconeogenic  enzymes  (red).  The  induction  of  gene  expression  by  insulin  is  mediated  by  the 
transcription factor sterol regulatory element binding protein (SREBP), the repression of expression 
is mediated by forkhead box O1 (FOXO1). Insulin also regulates the activity of glycogen synthase and 
citrate  lyase  (blue).  Insulin activates glycogen  synthase promoting  its dephosphorylation  through 
inhibition of protein kinase A (PKA) and glycogen‐synthase‐kinase‐3 (GSK‐3). IR, insulin receptor; 






phosphate  (F1P) antagonizes  the  inhibition of glucokinase  (GK) by glucokinase regulatory protein 
(GKRP) promoting  glucose  6‐phosphate  (G6P) production;  (2) newly  synthesized G6P  stimulates 
glycogen  synthase;  (3)  F1P  inhibits  glycogen  phosphorylase.  (B)  Fructose  6‐phosphate  (F6P)  and 
xylulose  5‐phosphate  (Xu‐5P)  activate  phosphoprotein‐phosphatase  2  which  activates 
phosphofructokinase 2 promoting generation of fructose 2,6‐bisphosphate (F2,6BP). F2,6BP activates 
Figure 1. Re lation of liver m tabolism by insulin. Insulin stimulates the expression of gen s encoding
glycolytic and lipogenic enzymes (green), but inhibits the expression of those encoding gluconeogenic
enzymes (red). The induction of gene expression by insulin is mediated by the transcription factor sterol
regulatory element binding protein (SREBP), the repression of expression is mediated by forkhead box
O1 (FOXO1). Insulin also regulates the activity of glycogen synthase and citrate lyase (blue). Insulin
activ t s glycogen synthase promoting its dephosphorylati n through in ibition of pr tein kinas A
(PKA) nd glycogen-synthase-kinase-3 (GSK-3). IR, insulin rece tor; GLUT2, glucose transporter 2;
PEPCK, phosphoenolpyruvate carboxykinase; ACC, acetyl-CoA carboxylase; FAS, fatty acid synthase
(Adapted from [51]).
3.1. Modulation of Glucose Uptake and Glycogenesis by Fructose
Small amounts of dietary fructose have been shown to dramatically increase the hepatic glucose
uptake through GK activation [52,53]. It is proposed that fructose 1-phosphate (F1P) antagonizes the
inhibition of GK by GKRP [44,54]. The allosteric activation of GS by increased G6P concentrations
and the simultaneous inhibition of glycogen phosphorylase by F1P may generate a glucose influx
into the hepatocyte [55,56] (Figure 2 shows hepatic glucose and fructose metabolism and illustrates
major regulatory mechanisms). A positive impact of small amounts of fructose on glycemic control,
and in particular on postprandial glucose levels, but also on long-term glycemic control (HbA1c) has
been reported in different human studies and meta-analyses with healthy individuals or patients with
diabetes [57–62]. In respect to glucose uptake and the formation of glycogen, small amounts of fructose
are contributing to the action of insulin.
However, the excess consumption of fructose (corresponding to the 90th percentile of fructose
intake of the US adults and above) has been shown to impair glucose uptake, reducing GK activity
and liver glycogen content [63]. While insulin signaling and GK mRNA levels remained unaffected
by fructose ingestion, GK and GKRP protein content was decreased. The underlying mechanisms
are not known. However, it is suggested that excess fructose consumption induces a significant
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posttranscriptional decrease in GK protein levels. In respect to glucose uptake and formation of
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phosphate  (F1P) antagonizes  the  inhibition of glucokinase  (GK) by glucokinase regulatory protein 
(GKRP) promoting  glucose  6‐phosphate  (G6P) production;  (2) newly  synthesized G6P  stimulates 
glycogen  synthase;  (3)  F1P  inhibits  glycogen  phosphorylase.  (B)  Fructose  6‐phosphate  (F6P)  and 
xylulose  5‐phosphate  (Xu‐5P)  activate  phosphoprotein‐phosphatase  2  which  activates 
phosphofructokinase 2 promoting generation of fructose 2,6‐bisphosphate (F2,6BP). F2,6BP activates 
Figure 2. Hepatic hexose uptake and regulatory mechanisms that control hexose breakdown.
Glucose and fructose is taken up by glucose transporter 2 (GLUT2). Fructose metabolites
regulate key enzymes of glucose metabolism. (A) Fructose stimulates glucose uptake by distinct
mechanisms:(1) Fructose 1-phosphate (F1P) antagonizes the inhibition of glucokinase (GK) by
glucokinase regulatory protein (GKRP) promoting glucose 6-phosphate (G6P) production; (2) newly
synthesized G6P stimulates glycogen synthase; (3) F1P inhibits glycogen phosphorylase. (B) Fructose
6-phosphate (F6P) and xylulose 5-phosphate (Xu-5P) activate phosphoprotein-phosphatase 2 which
activates phosphofructokinase 2 promoting generation of fructose 2,6-bisphosphate (F2,6BP). F2,6BP
activates phosphofructokinase 1 and inhibits F-1,6-bisphosphatase. (C) Insulin signaling increases
glucokinase expression and promotes glycogen synthesis enhancing glycogen-synthase-kinase-3
(GSK-3) phosphorlyation. (D) From metabolic control analysis it is concluded that in the fed,
hyperglycemic state, glucose exchange flux is controlled by GK, fructose-2,6-bisphosphatase, glucose
6-phosphatase (G6Pase) and phosphofructokinase-2 (orange box), while in the fasted, hypoglycemic
state pyruvate carboxylase, and lactate transporter control the glucose exchange flux [49]. IR, insulin
receptor; AMP, adenosine mono-phosphate; ATP, adenosine tri-phosphate. For completeness, the
illustration contains also some additional regulatory mechanisms not discussed in the article.
3.2. Conversion of Fructose into Glucose/Glycogen
It has been demonstrated that the consumption of dietary fructose compared to glucose induces
increased expression of the fructose metabolizing enzymes KHK, aldolase B and the glycolytic enzymes
PFK1 and PK [64] (Figure 3). Among the gluconeogenic enzymes, F1,6BPase and G6Pase are specifically
induced by dietary fructose. Yet, the underlying mechanism of fructose-induced gene expression is
unknown. However, a ChREBP driven mechanism that works independently from FOXO1 signaling
is suggested to induce G6Pase and F1,6BPase expression [64,65]. Based on these findings, one may
conclude that insulin and fructose exert the same enhancing effect on the expression of a subset
of glycolytic enzymes namely PFK1 and PK. However, with respect to gluconeogenic enzymes
F1,6BPase and G6Pase insulin and fructose show opposing effects. Additional data about the effects of
co-ingestion of glucose with fructose on the expression of gluconeogenic and glycolytic enzymes are
not available.





outcome  is unknown. However,  the metabolic outcome of  fructose  consumption with  respect  to 
gluconeogenesis  has  been  studied  using  tracer‐based  methods.  There  is  actually  significant 




Figure  3. Changes  of  hepatic  gene  expression  and metabolic  pathways  induced  by  fructose.  (A) 
Fructose  stimulates  the  expression  of  the  fructose  metabolizing  enzymes  (keto‐hexokinase  and 
aldolase B), glycolytic enzymes (phosphofructokinase 1, pyruvate kinase), but also the expression of 
gluconeogenic  enzymes  (glucose  6‐phosphatase  (G6Pase),  F‐1,6‐bisphosphatase,  pyruvate  kinase 
(green)). These effects are  thought  to be mediated by  transcription  factor carbohydrate responsive 
element binding protein (ChREBP). Fructose is suggested to increase xylulose‐5 phosphate (Xu‐5P) 
levels, which leads to nuclear translocation of ChREBP. It is suggested that fructose induced ChREBP 
activation dominates over  the  insulin and/or X‐Box Binding Protein 1  (XBP‐1)  suppressive effects 
mediated by forkhead box O1 (FOXO1) inhibition. (B) Increasing levels of uric acid from adenosine 
mono‐phosphate (AMP) catabolism increase mitochondrial oxidative stress. The resulting inhibition 
of  tricarboxylic acid  cycle  (TCA)  increases  the mitochondrial  citrate  release  stimulating  fatty acid 




limiting  step  in glycogen  synthesis  and  the  activity of glycogen phosphorylase.  It  is known  that 
insulin and G6P activate  the GS and F1P  inhibits glycogen phosphorylase. A  further  tracer study 
showed  that  fructose  contributes  little  to glycogen  synthesis when  ingested alone  (n = 6, healthy 
volunteers). However,  if  co‐ingested with  glucose,  fructose  contributes  significantly  to  glycogen 
synthesis  suggesting  a  critical  role  of  insulin  [69].  Insulin  stimulates  the  expression  of GK  and 
activates GS that catalyzes the rate limiting step in glycogen synthesis [72–74].   






Figure 3. Changes of hepatic gene expression and metabolic pathways induced by fructose.
(A) Fructose stimulates the expression of the fructose metabolizing enzymes (keto-hexokinase and
aldolase B), glycolytic enzymes (phosphofructokinase 1, pyruvate kinase), but also the expression
of gluconeogenic enzymes (glucose 6-phosphatase (G6Pase), F-1,6-bisphosphatase, pyruvate kinase
(green)). These effects are thought to be mediated by transcription factor carbohydrate responsive
element binding protein (ChREBP). Fructose is suggested to increase xylulose-5 phosphate (Xu-5P)
levels, which leads to nuclear translocation of ChREBP. It is suggested that fructose induced ChREBP
activation dominates over the insulin and/or X-Box Binding Protein 1 (XBP-1) suppressive effects
mediated by forkhead box O1 (FOXO1) inhibition. (B) Increasing levels of uric acid from adenosine
mono-phosphate (AMP) catabolism increase mitochondrial oxidative stress. The resulting inhibition of
tricarboxylic acid cycle (TCA) increases the mitochondrial citrate release stimulating fatty acid synthesis.
IR, insulin receptor; G6PD, glucose 6-phosphate dehydrogenase; PEPCK, phosphoenolpyruvate
carboxykinase; ATP, adenosine tri-phosphate.
Simultaneous enhancement of glycolytic enzyme expression by insulin and fructose, while
opposing eff cts on the expression of gluconeog nic enzymes appears paradoxical and raises the
question about the metabolic outcome when fructos and glucose are co-ingested. Does dietary fructose
promote futile cycling at the site of co version of F6P into F-1,6-bis os hate (F1,6BP) and vice versa
(Figure 2) [66]? What r effects of key i termediates such as fructose-2,6-bisphosphate (F2,6BP),
AMP and ATP? One important regulatory step during glycolysis is the conversion of F6P into F1,6BP
duri g glycolysis by PFK1 and the conversion of F1,6BP in F6P by F1,6BPa e during gluc neogenesis,
respect vely. While PFK1 is inhibited by high levels of ATP and induced by increased levels of F2,6BP
and F1,6BP, F1,6BPase is induced by high citrate levels and inhibit d by increased F2,6BP, F1,6BP, and
AMP levels. Thus, increased levels of F2,6BP genera ed by phosph rylation of F6P by PFK2, F1,6BP,
an AMP pro ote g ycolysis. F6P activates phosphoprote nph spha ase 2, which induces the kinase
activity of he bifunctional enzyme phosphofructokinase-2/fructose-2,6-bisphosphatase (PFKFB) and
thereby incr ases F2,6BP levels [67]. The relative impact of egulation of the expression of key enzymes
and th ir activity on the metabolic out me is unknown. However, the metabolic outcome of fructose
consumpti n with respect to gluconeogen sis has been studied using trace -based metho s. There is
actually significant gluconeogenesis from fructose also when co-ingested with glucose [68,69]. The
impact of fructose consumption on blood glucose concentration and glycemic control has been the
subject of extensive meta-analyses [70,71].
Newly generated glucose from fructose is released into the plasma, but is there also deposition
in the glycogen storage? Glycogen deposition depends on the activity of GS that catalyzes the rate
limiting step in glycogen synthesis and the activity of glycogen phosphorylase. It is known that
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insulin and G6P activate the GS and F1P inhibits glycogen phosphorylase. A further tracer study
showed that fructose contributes little to glycogen synthesis when ingested alone (n = 6, healthy
volunteers). However, if co-ingested with glucose, fructose contributes significantly to glycogen
synthesis suggesting a critical role of insulin [69]. Insulin stimulates the expression of GK and activates
GS that catalyzes the rate limiting step in glycogen synthesis [72–74].
The described mechanisms explain how fructose and glucose may act as molecules that modulate
the metabolic fate of each other. Both energy carriers compete for glycogen storage capacity and access
to the tricarboxylic acid cycle (TCA) and fatty acid synthesis pathways.
Fructose was primarily described as “lipogenic substrate” in the context of hepatic metabolism,
however, studies demonstrate that gluconeogenesis and glycogen deposition also play an important
role in fructose metabolism. The metabolic effects of fructose consumption are dose-dependent. Small
amounts of fructose may substantially enhance the uptake of glucose into the liver and glycogen
deposition, while large amounts of fructose may reduce the hepatic glucose uptake. The presence of
insulin determines the fate of fructose. The fact that co-ingestion with glucose directs fructose to the
glycogen storage probably through the action of insulin would suggest that glucose takes temporarily
the load off the other fructose disposal pathways.
4. Lipogenesis
De novo lipogenesis (DNL) is the conversion of carbohydrates or proteins into fatty acids, enabling
the organism to store energy in an unlimited way as fat. DNL takes place in the cytosol of hepatocytes
and adipocytes if there is an excess of the substrate acetyl co-enzyme A. Critical enzymes of the
synthesis pathway of fatty acids are the Acetyl CoA Carboxylase (ACC), the fatty acid synthase (FAS),
elongation of long-chain fatty acids family member 6 (ELOVL6), as well as stearoyl-CoA desaturase 1
(SCD1) [75–78]. Increased availability of acetyl co-enzyme A substrate and elevated enzyme activities
and quantities have been shown to directly enhance the output of newly synthesized fatty acids, such
as palmitate and stearate. As illustrated above, studies point out that fructose probably increases the
levels of lipogenic substrates more as compared to glucose ingested alone. Fructose as well as glucose
induce transcription of lipogenic enzymes. The question of whether lipogenic enzymes are induced
directly by carbohydrates or indirectly by the stimulation of insulin secretion raises the issue of sugar
specific impacts on liver metabolism. Are there any hexose specific processes regulating lipogenesis?
4.1. Transcriptional Regulation of the Expression of Lipogenic Enzymes by Carbohydrates
There are several master transcription factors regulating the expression of partly the same set of
lipogenic enzymes. ChREBP induces the transcription of FAS, SCD1, ELOVL6, ACC, and PK [79,80].
SREBP1c upregulates the expression of FAS, ACC, stearoyl-CoA desaturase 1 SCD1, ELOVL6 [81,82].
X-Box Binding Protein 1 (XBP-1), known as mediator of the endoplasmic reticulum (ER) stress response,
has been attributed an additional function as a transcription factor of the lipogenic genes FAS, SCD1,
ACC 1 and ACC 2 [83].
4.1.1. ChREBP
Hepatic ChREBP expression is induced by a high-carbohydrate diet [79,84]. Feeding studies
comparing the potency of fructose versus glucose to induce ChREBP expression have shown different
outcomes: two studies report that fructose more potently induced ChREPB expression [64,65], whereas
another study reported no differences [85]. Although it is suggested that insulin too is implicated in
the regulation of ChREBP expression [86], liver insulin receptor knock-out mice show an increased
ChREBP expression after ad libitum chow feeding [85]. There are two ChREBP isoforms identified:
ChREBPα and ChREBPβ. The specific roles of the isoforms are not yet clear. It is thought that glucose
first induces the expression of ChREBPα by inducing the transcription of ChREBPβ, which in turn is
supposed to be the more potent isoform [86,87]. While only little is known about the transcriptional
regulation of ChREBP, post-translational regulation of ChREBP has extensively been investigated
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(Figure 4). Intermediates of the glycolytic pathway and the pentose pathway play an important role in
the regulation of ChREBP activity [88–90]. Entrance into the nucleus and binding to the DNA binding
site CHoRE are regulated by G6P, xylulose 5-phosphate (Xu-5P), and F2,6P via the post-translational
modification of ChREBP enhancing DNA binding and transcriptional activity.Nutrients 2017, 9, 1026  8 of 20 
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Figure 4. Carbohydrate induced expression of lipogenic genes. (1) Activation of carbohydrate
responsive element binding protein (ChREBP): xylulose 5-phosphate (Xu-5P), glucose 6-phosphate
(G6P), and fructose-2,6-bisphosphate (F2,6BP) promote nuclear entry of ChREBP. (2) Sterol regulatory
element binding protein-1c (SREBP-1c) transcription and dependent expression of lipogenic enzymes is
mediated by mechanistic target of rapamycin C1 (mTORC1) signaling. mTORC1 is induced by insulin
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The underlying mechansims are unknown.
Overall, any hexose pathway that e ds in the gluconeogenetic pathway at the level of
trioses (dihydroxyacetone phosphate and g yceraldehyde) potentially e hances ChREBP d pendent
expression of lipogenic enzymes. Fructose may directly activate ChREBP through fructose derived
intermediates or indirectly through activation of GK enhancing t fl i rt ce of
l ti of hexose metabolism is reflected in ChREBP deficient mice which show
glycogen accumulation an decreased triglyceride (TAG) synthe is in the liver [91].
4.1.2. SREBP1c
There are three SREBP isoforms, SREBP-1a, -1c and 2. SREBP1c is known to induce lipogenic
gene expression and its expression itself is induced by carbohydrate feeding. Ad libitum chow-feeding
of mice (24 h, fed state) increased SREBP1c expression in wildtype mice and to a lesser extent also
in liver insulin receptor knock-out mice (LIRKO) [85]. SREBP1c expression is known to be regulated
by a mechanistic target of rapamycin C1 (mTORC1), which is activated by carbohydrate feeding as
well as by insulin signaling. It is thought that insulin is necessary for a maximal induction of SREBP1c
expression by carbohydrate feeding.
The potential of fructose to induce SREBP1c expression has also been examined in mice. The
impact of a 1- eek high-fructose diet (60% fructose) was compared to a standard chow diet on SREBP1c
expression. Fructose diet increased SREBP1c mRNA levels and consequently the mRNA levels of
lipogenic enzymes more potently than standard chow diet in wildtype, as well as in LIRKO mice.
Levels of nuclear SREBP1c protein in LIRKO mice are lower than in wildtype mice after both fructose
and standard chow diet indicating the important role of insulin signaling.
Insulin binding to the insulin receptor activates the phosphoinositid-3-kinase/protein kinase B
(PI3K/PKB) pathway and results in the proteolytic activation of SREBP1c through the interaction
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of SCAP (SREBP cleavage-activating protein) and INSIG1 (insulin-induced gene-1), and its release
from the Golgi apparatus [92]. Mice with conditional SCAP deficiency in the liver (L-SCAP-mice) and
therefore no functional SREBP isoforms show a reduced hepatic FA synthesis [93]. Livers of these mice
show reduced mRNA levels of lipogenic enzymes and do not respond with an increase in mRNA levels
upon insulin stimulation. Their very low density lipoprotein (VLDL) levels in the plasma are reduced.
In L-SCAP-mice, there is a compensatory increase in fatty acid synthesis in adipose tissue [94].
4.1.3. XBP-1
XBP-1 is an active transcription factor which increases the ER folding capacity in response to ER
stress (unfolded protein response (UPR)) [83]. Apart from this central role, XBP-1 has been identified
as regulator of hepatic DNL. Specific deletion of XBP-1 in the adult liver reduces plasma TAG and is
thought to reduce lipids synthesis in the liver [95]. In wildtype mice but not XBP-1 knock-out mice,
carbohydrate feeding induces hepatic expression of FAS, SCD1, ACC 1, and ACC 2. A high-fructose
diet compared to a standard chow diet induces the expression XBP-1 more potently. The signal that
activates XBP-1 upon carbohydrate feeding and how/whether it relates to ER stress is unknown [83].
It has been shown that XBP-1 inhibits FOXO1 signaling suppressing the expression of gluconeogenic
enzymes [96].
Although mechanisms are described that involve insulin in the regulation of the expression of
both ChREBP and SREBP1c, feeding studies with insulin receptor knock-out mice show that insulin
is required neither for the induction of ChREBP nor for SREBP1c. However, in the case of SREBP1c
the presence of insulin is required for a full induction of SREBP1c expression upon carbohydrate
consumption. ChREBP, SREBP1c and XBP-1 are more potently induced by a high-fructose compared
to high-glucose diet [64,65,83,85]. Consequently, lipogenic gene expression is also significantly more
increased by fructose compared with a glucose diet. Overall, there is evidence that fructose is more
potent than glucose in respect to the induction of lipogenic gene expression.
4.2. Stimulation of DNL by Fructose via Purine Degradation
Rapid phosphorylation of fructose by KHK decreases ATP levels, paralleled by an increase in
AMP levels [97,98]. It has been shown that AMP enters into the purine degradation pathway through
the activation of AMP deaminase resulting in uric acid production and the generation of mitochondrial
oxidants. There is evidence that fructose via a purine-degrading pathway stimulates triglyceride
synthesis [97]. The inhibition of aconitase within the TCA cycle by mitochondrial oxidative stress leads
to the accumulation of citrate, the stimulation of ATP citrate lyase, and fatty-acid synthase leading
to DNL.
4.3. Stimulation of Fatty Acid Synthesis by Carbohydrates—Results from Isotopic Tracer Studies
It is an open question, to which extent de novo lipogenesis (DNL) from carbohydrates is
contributing to TAG synthesis/secretion or eventually to the TAG accumulation in hepatocytes. In the
past, studies have addressed this issue by using isotope-based methods for the measurement of de novo
lipogenesis. After the consumption of different kinds and amounts of sugars, rates of secretion of newly
synthesized palmitate, or the fractional de novo lipogenesis (the proportion of newly synthesized
palmitate of the totally secreted palmitate) have been calculated in different experimental settings.
Here, two studies should be mentioned that applied the mass isotopomer distribution analysis (MIDA)
approach for which 13C-acetate is infused and 13C-palmitate isotopomers from isolated VLDLs are
measured. In one study, the short-term effects of a hypercaloric carbohydrate (hydrolyzed corn starch)
feeding on fatty acid synthesis were examined in healthy men (n = 5). A hypercaloric carbohydrate
diet (around 2.5 times energy expenditure) during four days generated moderate hyperinsulinemia
and increased VLDL-TAG concentrations. It caused an increase in the secretion rate of VLDLs, newly
synthesized palmitate and preformed fatty acids, and a decreased VLDL-TAG catabolism [99]. The
other study compared the short-term effects of an energy-balanced high-fructose diet (25% energy
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intake) with the effects of a complex carbohydrate diet with low-fructose (5% energy intake) on
fractional DNL in healthy men (n = 8). After six days of this diet, there was no significant difference in
respect to the fasting fractional DNL [100]. In contrast, postprandial fractional DNL after 9 days of
diet indicated as integrated DNL (area under the curve) was increased during the high-fructose diet
when compared with the complex carbohydrate diet. A further study demonstrated that moderate
aerobic exercise neutralizes the effects of an energy-balanced high-fructose diet on postprandial TAG
concentrations and DNL [101]. It was speculated that DNL was decreased due to a reduced availability
of fructose substrate for lipogenesis during exercise.
The focus of further studies should be on the long-term effects of free fructose versus free glucose
on DNL in energy-balanced diets. They should aim for the determination of the rate of secretion of
newly synthesized and preformed FA induced by high-glucose vs. -fructose diets. Further information
about the impact of sugar type on liver metabolism is needed.
5. Fatty Acid Oxidation
During the fasted state, mitochondrial fatty acid oxidation produces energy in the liver. Beta
oxidation provides energy for the hepatocyte and also ketone bodies that are exported to extrahepatic
tissues. Beta oxidation is regulated at several stages.
Peroxisome proliferator-activated receptor alpha (PPAR α) is a master regulator of hepatic lipid
metabolism and its expression is induced in the fasted state [102]. It is induced by glucagon and it is
activated by a subtype of longchain fatty acids (LCFA) and phospatidylcholines [103,104].
PPAR α controls the fatty acid import into and processing within the mitochondria by carnitine
palmitoyltransferase 1 (CPT-1) and important enzymes of the beta oxidation pathway, such as
acyl-CoA dehydrogenases (Acad) [105,106]. Fructose has been shown to decrease beta oxidation
by downregulation of PPARα [107]. Dietary unsaturated fatty acids showed a favorable effect on
hepatic gene expression mediated by PPARα and mimic the effect of synthetic PPARα agonists [108].
The rate limiting step of beta oxidation is the translocation of LCFA into the mitochondrium
mediated by CPT-1. Malonyl-CoA, produced by carboxylation of acetyl CoA by ACC2, is inhibiting
CPT-1. Malonyl-CoA is the primary substrate for lipogenesis and by inhibiting CPT-1 it avoids a futile
cycle [109–112]. Ongoing fatty acid synthesis from carbohydrates interferes with the beta oxidation
via malonyl-CoA.
The effect of low- and high-carbohydrate diets on substrate oxidation has been investigated in
healthy men (n = 5) by using stable-isotope methodology and indirect calorimetry. Two weeks of a
high-carbohydrate diet (75% carbohydrates, 10% fat, 15% protein) significantly reduced the total and
plasma fatty acid oxidation when compared to a 2-week low-carbohydrate diet (30% carbohydrates,
55% fat, 15% protein) [113]. It was shown that there is a carbohydrate-induced inhibition LCFA entry
into the mitochondria using tracer methodology [114]. Oxidation of 13C-LCFA and 14C-medium-chain
fatty acid (MCFA) was measured during hyperglycemic and hyperinsulinemic clamps. Entrance of
LCFA but not of MCFA into the mitochondria is known to depend on CPT 1. Only the oxidation
of LCFA but not of MCFA was significantly reduced. This suggests that carbohydrates inhibit fatty
oxidation by inhibition of CPT1/entrance of LCFA into the mitochondria. To our knowledge, there is
no study directly comparing the effects of high-fructose and -glucose energy balanced diets on fatty
acid oxidation.
6. TAG Synthesis and VLDL Secretion
The primary determinant for TAG synthesis and secretion is the availability of free fatty acids
in the liver [115,116]. Fatty acids (FA) in the liver are of different origin [117,118]. They can be non
esterified fatty acids (NEFA) released into the plasma by adipocytes, fatty acids newly synthesized
by the liver, or dietary fatty acids. The proportion of FA from the different sources depends critically
on the metabolic state. During the fed state, the proportion of NEFA from adipose tissue declines as
lipolysis is turned off by insulin. In contrast, DNL is increased as lipogenic substrates are available
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from carbohydrate catabolism and by the stimulatory effect of insulin on fatty acid synthesis. Newly
synthesized malonyl-CoA suppresses fat oxidation. Postprandially, the dietary fatty acids in the
liver increase due to the spillover of lipoprotein lipase (LPL)-generated fatty acids and TAG delivery
by chylomicron remnants [119]. In the fasted state, the proportions are reversed. FA from lipolysis
increases, DNL declines and the supply of dietary fatty acids ceases.
The rate of the hepatic uptake of NEFAs is given by the plasma NEFA concentration and the
amount and activity of transporter protein [120]. NEFAs from the plasma enter the hepatocyte
mainly via fatty acid transport protein (FATP) and are activated to fatty acid CoA. FA are activated
to acyl-CoA in the hepatocyte in a largely unknown process. Three acyl-CoA from entered
fatty acids/preformed fatty acids or newly synthesized fatty acids are sequentially esterified
involving different transferases (glycerol phosphate acyltransferase (GPAT), acylglycerolphosphate
acyltransferase (AGPAT), diacylglycerolphosphate acyltransferase (DGAT)) to a glycerol molecule
to build TAG. TAGs are packaged with apoB 100 to VLDL in the ER by the microsomal TAG
transfer protein (MTP). Insulin acts as a regulator of VLDL assembly and secretion. Insulin induces
apolipoprotein B 100 (ApoB 100) degradation limiting the postprandial secretion of VLDL [121].
The effects of fructose consumption on TAG concentrations has not been comprehensively
clarified. On the one hand, there is evidence that carbohydrate and high-fructose intake significantly
increase the blood TAG concentrations probably due to stimulation of DNL and VLDL secretion in
weight-maintaining diets [100,122–125]. In addition, a high-fructose intake may impair postprandial
TAG clearance possibly due to decreased insulin levels and consequently decreased the activity
of lipoproteinlipase [126]. On the other hand, data from meta-analyses show that while isocaloric
exchange for other carbohydrate does not increase postprandial triglycerides and has no negative
effects on established lipid parameters [127], fructose providing excess energy does increase
postprandial triglycerides. Longer and larger trials on this topic are needed—as concluded by a
systematic review and meta-analysis of controlled feeding trials [128]. Current literature delivers quite
heterogeneous results regarding the effect of isocaloric fructose exchange for carbohydrate on blood
lipids [129].
A fructose-induced increase of de novo fatty acid synthesis and a decrease of beta oxidation is
supposed to increase hepatic FA content and to enhance TAG synthesis and VLDL secretion (Figure 5).
While a hypercaloric high-fructose diet is associated with an increase in intrahepatocellular lipid
content (IHLC), isocaloric exchange of fructose for other carbohydrates does not increase IHLC
in healthy participants [130]. However, there is also a study reporting an increased IHLC with a
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Figure 5. epatic triglyceride (TAG) synthesis and very low density lipoprotein (VLDL) secretion. The
abundance of fatty acids (FA) in the liver is given by the plasma concentration of dietary FA and non
esterified fatty acids (NEFA) and the amounts of newly synthesized FA and beta oxidation rate. It is the
main determinant of the hepatic TAG/VLDL secretion rate. FA are sequentially esterified with glycerol
by different transferases and secreted as VLDL. Fructose decreases beta oxidation and increases hepatic
FA/TAG content and VLDL secretion.
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7. Association of Chronic Fructose Consumption with Reduced Insulin Sensitivity and
Continuous Hepatic Production of Glucose
Potential implications of high-fructose consumption on insulin sensitivity and blood lipids have
been examined extensively. Fructose has generally been recognized as sugar that decreases insulin
sensitivity and promotes dyslipidemia [131,132].
Focusing on the effects of fructose consumption in healthy men, a study by Aeberli et al. examined
the implications of fructose ingestion in amounts close to usual daily consumption when soft drinks
replace unsweetened beverages (n = 9). The study assessed the effects of moderate amounts of fructose
and sucrose as compared with glucose on insulin sensitivity and lipid metabolism. Moderate amounts
of fructose consumption impair insulin sensitivity in healthy young men, without affecting plasma
glucose and TAG levels [133]. Of interest, it was in particular the suppression of hepatic glucose
production that could be detected by the use of euglycemic-hyperinsulinemic clamp technique.
Further evidence that fructose consumption reduces hepatic insulin sensitivity and induces
hyperglycemia comes from studies where hepatic fructose uptake was prevented. An animal study
presenting a KHK knock-out mouse (KHK-A/C deletion) confirmed a pivotal role of KHK in the
regulation of hepatic fructose uptake. The deletion of KHK abolished hepatic fructose uptake and led
to a dramatic hyperfructosemia, but prevented fructose-induced hyperglycemia [134]. In particular,
the impact of chronic fructose consumption on plasma glucose concentrations in KHK knock-out
mice vs. wildtype mice was compared. After 12-weeks of ad libitum fructose feeding, there was
fructose-induced hyperglycemia in wildtype mice with associated increased HbA1c levels, but not in
KHK-/- mice.
The precise mechanisms underlying fructose induced hepatic insulin insensitivity are still
unknown. Lines of research currently focus on mechanisms driving gluconeogenesis by increasing
expression of gluconeogenic enzymes namely PEPCK, F1,6BPase and G6Pase. Yet, there are also
studies examining the impact of high-fructose diets on hepatic glucose uptake as well as glycogen
formation [63] (Figure 6).
In rats, a long-term high-fructose, but not -glucose (eucaloric) diet caused hepatic deposition
of TAG and impaired insulin signaling and glucose tolerance, but did not change the expression of
PEPCK (fasted state) [135]. Also in mice, long-term high fructose as well as glucose feeding did not
alter PEPCK expression (fed and fasted state) [64]. Another study investigated the acute effect of
fructose on PEPCK expression. It is suggested that fructose consumption increases the hepatic PEPCK
gene expression via the activation of hypothalamic 5′-AMP-activated protein kinase (AMPK) [136].
Fructose, at least in a rodent model, may increase corticosterone levels through a mechanism that is
dependent on hypothalamic AMPK activation resulting in an increased hepatic PEPCK expression,
although these conclusions remain speculative for the time-being. The role of PEPCK for fructose
induced insulin sensitivity has not yet been conclusively defined.
Further studies suggest that fructose feeding increases the expression of the gluconeogenic
enzymes F1,6BPase and also G6Pase driving hepatic gluconeogenesis and glucose release [64,65]. It is
suggested that a carbohydrate-mediated ChREBP-driven FOXO independent mechanism induces
F1,6BPase and G6Pase expression. In addition, it is hypothesized that an increased G6Pase activity
may decrease hepatic G6P levels, which could stimulate glycogen breakdown. The resulting increase
of hepatic glucose release could promote hyperinsulinemia and insulin insensitivity.
Furthermore, as mentioned earlier, excessive fructose consumption may lead to decreased GK
levels, hepatic glucose uptake, and further decreased GS activity resulting in decreased glycogen
deposition [63].
Overall, even though long-term fructose consumption (supplementation of eucaloric 10% w/v
fructose or glucose solutions for 2 months, ad libitum fed rat) increased hepatic TAG content and
decreased hepatic insulin receptor 2 (IR-2) expression and Akt activation, the impact on hepatic
metabolism has to be further clarified [135]. Namely, whether it leads to decreased glycogen synthase
activity due to decreased GSK-3 activity as reported for high fat diet induced-fatty liver remains
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elusive [137]. The impact of increased hepatic TAG fat has generally been associated with decreased
insulin sensitivity. There are opposing data whether fructose consumption leads to ER stress associated
with decreased insulin sensitivity [83,138]. A study investigated the potential role of increased TAG as
a trigger for ER stress that could induce insulin insensitivity. XBP-1 knockout mice showed increased
expression of ER stress markers but lower TAG levels when compared with wildtype mice after
a 1-week fructose diet. Insulin sensitivity in XBP-1 knock-out mice was increased as compared to
wildtype mice. From these data it was concluded that ER stress can be disassociated from hepatic
insulin resistance supporting the hypothesis that hepatic insulin resistance in models of ER stress may
be secondary to ER stress modulation of hepatic lipogenesis [138].
Research about fructose induced insulin insensitivity has been strongly focused on the gene
expression of metabolic enzymes. The impact of fructose on the hepatic allosterome and thereby on
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fructose  intake with  an  energy‐balanced diet  on  liver  fat  content may  need  further  examination 
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Figure 6. Proposed hypotheses explaining hepatic insulin resistance induced by fructose. (1) Increased
diacylglycerols (DAG) levels activate (protein kinase C-ε) PKC-ε leading via a cascade of
serine-threonine kinases finally to a decreased tyrosine phosphorylation of insulin receptor 1
and 2 (IR-1,-2) which interferes with insulin signaling. Consequently, glycogen synthase activity
decreases. (2) Fructose-induced hypothalamic activation of 5′-AMP-activated protein kinase (AMPK)
increases via an unknown effector corticosterone release by the adrenal gland. The resulting
enhanced phosphoenolpyruvate carboxykinase (PEPCK) expression increases gluconeogenesis.
(3) Fructose-induced glucose-6-phosphatase (G6Pase) activity has been identified as main determinant
of hepatic glucose production dominating over the suppressive effects of insulin. (4) Excessive fructose
consumption may induce a significant posttranscriptional decrease in glucokinase (GK) protein levels.
(5) Fructose decreases IR-2 expression.
8. Conclusions
After 50 years of research, there is sound evidence that fructose can be qualified as glucogenic
and lipogenic sugar. A central role in the hepatic hexose metabolis play the transcription factors
ChREBP and SREBP1c, both ore potently induced by fructose than by glucose. This see s to reflect
the i portance of the liver for fructose etabolis . Consequently, fructose consu ption ay i pair
glucose homeostasis by increased expression of the gluconeogenic enzymes counteracting the effect of
insulin. On the other hand, fructose may lead to an increased expression of lipogenic enzymes with
i plications on blood TAG and intrahepatic TAG concentrations.
The i pact of fructose on etabolic parameters, as assessed by feeding-trials, is dose-dependent,
with probably little effect when low dosages of fructose are used as isocaloric substitution for
Nutrients 2017, 9, 1026 14 of 21
glucose [139–143]. Similarly, there is a consensus on the TAG raising effects of excessive fructose
consumption, but inconsistent data about the effects of a high-fructose energy balanced diet on
VLDL secretion and TAG concentrations [139]. While excessive fructose consumption increases
IHLC, the effects of high-fructose intake with an energy-balanced diet on liver fat content may need
further examination [100,130]. Catalytic amounts of fructose may enhance hepatic glucose uptake via
activation of GK, excessive fructose consumption may impair glucose tolerance decreasing GK levels.
Overall, fructose consumption has been shown to promote hepatic insulin resistance in
non-diabetic men [131,133], as well as in rodents [138,144]. Reduced insulin sensitivity with continuous
hepatic production and a release of glucose in the fed state is thought to result in long-term
hyperglycemia and hyperinsulinemia and to impair muscle insulin sensitivity, and thereby promoting
the development of type 2 diabetes mellitus.
However, the debate about the limit between harmless and harmful quantities of fructose is still
ongoing, and larger and longer feeding trials are needed in order to complete existing evidence and to
increase our understanding of the topic.
In the future, mathematical models may enhance our understanding of the role of fructose in
glucose flux control and will be useful for the design of new experiments [49].
Acknowledgments: Bettina Geidl-Flueck was supported by grants of the Swiss National Science Foundation
(SNSF Grant 144204), Vontobel-Stiftung, Promedica-Stiftung and Uniscientia-Stiftung. We thank Giatgen Andreia
Spinas for critical review of the manuscript.
Conflicts of Interest: The authors declare no conflict of interests.
References
1. Williams, C.D.; Stengel, J.; Asike, M.I.; Torres, D.M.; Shaw, J.; Contreras, M.; Landt, C.L.; Harrison, S.A.
Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged
population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology 2011, 140, 124–131.
[CrossRef] [PubMed]
2. Afshin, A.; Forouzanfar, M.H.; Reitsma, M.B.; Sur, P.; Estep, K.; Lee, A.; Marczak, L.; Mokdad, A.H.;
Moradi-Lakeh, M.; Naghavi, M.; et al. Health Effects of Overweight and Obesity in 195 Countries over
25 Years. N. Engl. J. Med. 2017, 377, 13–27. [PubMed]
3. Menke, A.; Casagrande, S.; Geiss, L.; Cowie, C.C. Prevalence of and Trends in Diabetes Among Adults in the
United States, 1988–2012. JAMA 2015, 314, 1021–1029. [CrossRef] [PubMed]
4. DiNicolantonio, J.J.; O’Keefe, J.H.; Lucan, S.C. Added fructose: A principal driver of type 2 diabetes mellitus
and its consequences. Mayo Clin. Proc. 2015, 90, 372–381. [CrossRef] [PubMed]
5. Sievenpiper, J.L.; Tappy, L.; Brouns, F. Fructose as a Driver of Diabetes: An Incomplete View of the Evidence.
Mayo Clin. Proc. 2015, 90, 984–988. [CrossRef] [PubMed]
6. DiNicolantonio, J.J.; O’Keefe, J.H.; Lucan, S.C. In reply—Fructose as a Driver of Diabetes: An Incomplete
View of the Evidence. Mayo Clin. Proc. 2015, 90, 988–990. [CrossRef] [PubMed]
7. Thorens, B.; Mueckler, M. Glucose transporters in the 21st Century. Am. J. Physiol. Endocrinol. Metab. 2010,
298, E141–E145. [CrossRef] [PubMed]
8. Colville, C.A.; Seatter, M.J.; Jess, T.J.; Gould, G.W.; Thomas, H.M. Kinetic analysis of the liver-type (GLUT2)
and brain-type (GLUT3) glucose transporters in Xenopus oocytes: Substrate specificities and effects of
transport inhibitors. Biochem. J. 1993, 290, 701–706. [CrossRef] [PubMed]
9. Thorens, B. Molecular and cellular physiology of GLUT-2, a high-Km facilitated diffusion glucose transporter.
Int. Rev. Cytol. 1992, 137, 209–238. [PubMed]
10. Eny, K.M.; Wolever, T.M.; Fontaine-Bisson, B.; El-Sohemy, A. Genetic variant in the glucose transporter type
2 is associated with higher intakes of sugars in two distinct populations. Physiol. Genom. 2008, 33, 355–360.
[CrossRef] [PubMed]
11. Douard, V.; Ferraris, R.P. Regulation of the fructose transporter GLUT5 in health and disease. Am. J. Physiol.
Endocrinol. Metab. 2008, 295, E227–E237. [CrossRef] [PubMed]
Nutrients 2017, 9, 1026 15 of 21
12. Kane, S.; Seatter, M.J.; Gould, G.W. Functional studies of human GLUT5: Effect of pH on substrate selection
and an analysis of substrate interactions. Biochem. Biophys. Res. Commun. 1997, 238, 503–505. [CrossRef]
[PubMed]
13. Burant, C.F.; Takeda, J.; Brot-Laroche, E.; Bell, G.I.; Davidson, N.O. Fructose transporter in human
spermatozoa and small intestine is GLUT5. J. Biol. Chem. 1992, 267, 14523–14526. [PubMed]
14. Patel, C.; Douard, V.; Yu, S.; Gao, N.; Ferraris, R.P. Transport, metabolism, and endosomal
trafficking-dependent regulation of intestinal fructose absorption. FASEB J. 2015, 29, 4046–4058. [CrossRef]
[PubMed]
15. Shu, R.; David, E.S.; Ferraris, R.P. Dietary fructose enhances intestinal fructose transport and GLUT5
expression in weaning rats. Am. J. Physiol. 1997, 272, G446–G453. [PubMed]
16. Shu, R.; David, E.S.; Ferraris, R.P. Luminal fructose modulates fructose transport and GLUT-5 expression in
small intestine of weaning rats. Am. J. Physiol. 1998, 274, G232–G239. [PubMed]
17. Patel, C.; Douard, V.; Yu, S.; Tharabenjasin, P.; Gao, N.; Ferraris, R.P. Fructose-induced increases in expression
of intestinal fructolytic and gluconeogenic genes are regulated by GLUT5 and KHK. Am. J. Physiol. Regul.
Integr. Comp. Physiol. 2015, 309, R499–R509. [CrossRef] [PubMed]
18. Suzuki, T.; Douard, V.; Mochizuki, K.; Goda, T.; Ferraris, R.P. Diet-induced epigenetic regulation in vivo of
the intestinal fructose transporter Glut5 during development of rat small intestine. Biochem. J. 2011, 435,
43–53. [CrossRef] [PubMed]
19. Gorboulev, V.; Schurmann, A.; Vallon, V.; Kipp, H.; Jaschke, A.; Klessen, D.; Friedrich, A.; Scherneck, S.;
Rieg, T.; Cunard, R.; et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption
and glucose-dependent incretin secretion. Diabetes 2012, 61, 187–196. [CrossRef] [PubMed]
20. Kellett, G.L.; Brot-Laroche, E.; Mace, O.J.; Leturque, A. Sugar absorption in the intestine: The role of GLUT2.
Annu. Rev. Nutr. 2008, 28, 35–54. [CrossRef] [PubMed]
21. Roder, P.V.; Geillinger, K.E.; Zietek, T.S.; Thorens, B.; Koepsell, H.; Daniel, H. The role of SGLT1 and GLUT2
in intestinal glucose transport and sensing. PLoS ONE 2014, 9, e89977. [CrossRef] [PubMed]
22. Koepsell, H.; Gorboulev, V. Response to Comment on: Gorboulev et al. Na(+)-D-glucose Cotransporter
SGLT1 Is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion. Diabetes 2012,
61. [CrossRef]
23. Kellett, G.L. Comment on: Gorboulev et al. Na(+)-D-glucose cotransporter SGLT1 Is pivotal for intestinal
glucose absorption and glucose-dependent incretin secretion. Diabetes 2012, 61, e4. [CrossRef] [PubMed]
24. Cui, X.L.; Soteropoulos, P.; Tolias, P.; Ferraris, R.P. Fructose-responsive genes in the small intestine of neonatal
rats. Physiol. Genom. 2004, 18, 206–217. [CrossRef] [PubMed]
25. Mendeloff, A.I.; Weichselbaum, T.E. Role of the human liver in the assimilation of intravenously administered
fructose. Metabolism 1953, 2, 450–458. [PubMed]
26. Bjorkman, O.; Felig, P. Role of the kidney in the metabolism of fructose in 60-hour fasted humans. Diabetes
1982, 31, 516–520. [CrossRef] [PubMed]
27. Bergstrom, J.; Hultman, E. Synthesis of muscle glycogen in man after glucose and fructose infusion.
Acta Med. Scand. 1967, 182, 93–107. [CrossRef] [PubMed]
28. Froesch, E.R.; Ginsberg, J.L. Fructose metabolism of adipose tissue. I. Comparison of fructose and glucose
metabolism in epididymal adipose tissue of normal rats. J. Biol Chem. 1962, 237, 3317–3324. [PubMed]
29. Kayano, T.; Burant, C.F.; Fukumoto, H.; Gould, G.W.; Fan, Y.S.; Eddy, R.L.; Byers, M.G.; Shows, T.B.; Seino, S.;
Bell, G.I. Human facilitative glucose transporters. Isolation, functional characterization, and gene localization
of cDNAs encoding an isoform (GLUT5) expressed in small intestine, kidney, muscle, and adipose tissue and
an unusual glucose transporter pseudogene-like sequence (GLUT6). J. Biol Chem. 1990, 265, 13276–13282.
[PubMed]
30. Karnieli, E.; Armoni, M. Transcriptional regulation of the insulin-responsive glucose transporter GLUT4
gene: From physiology to pathology. Am. J. Physiol. Endocrinol. Metab. 2008, 295, E38–E45. [CrossRef]
[PubMed]
31. Zhao, F.Q.; Keating, A.F. Functional properties and genomics of glucose transporters. Curr. Genom. 2007, 8,
113–128. [CrossRef]
Nutrients 2017, 9, 1026 16 of 21
32. Ishimoto, T.; Lanaspa, M.A.; Le, M.T.; Garcia, G.E.; Diggle, C.P.; Maclean, P.S.; Jackman, M.R.; Asipu, A.;
Roncal-Jimenez, C.A.; Kosugi, T.; et al. Opposing effects of fructokinase C and A isoforms on
fructose-induced metabolic syndrome in mice. Proc. Natl. Acad. Sci. USA 2012, 109, 4320–4325. [CrossRef]
[PubMed]
33. Mayes, P.A. Intermediary metabolism of fructose. Am. J. Clin. Nutr. 1993, 58, 754S–765S. [PubMed]
34. Hers, H.G. Liver fructokinase. Biochim. Biophys. Acta 1952, 8, 416–423. [CrossRef]
35. Mirtschink, P.; Krishnan, J.; Grimm, F.; Sarre, A.; Horl, M.; Kayikci, M.; Fankhauser, N.; Christinat, Y.;
Cortijo, C.; Feehan, O.; et al. HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease.
Nature 2015, 522, 444–449. [CrossRef] [PubMed]
36. Li, X.; Qian, X.; Peng, L.X.; Jiang, Y.; Hawke, D.H.; Zheng, Y.; Xia, Y.; Lee, J.H.; Cote, G.; Wang, H.; et al.
A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation.
Nat. Cell. Biol. 2016, 18, 561–571. [CrossRef] [PubMed]
37. Elliott, S.S.; Keim, N.L.; Stern, J.S.; Teff, K.; Havel, P.J. Fructose, weight gain, and the insulin resistance
syndrome. Am. J. Clin. Nutr. 2002, 76, 911–922. [PubMed]
38. Iynedjian, P.B. Mammalian glucokinase and its gene. Biochem. J. 1993, 293, 1–13. [CrossRef] [PubMed]
39. Nouspikel, T.; Iynedjian, P.B. Insulin signalling and regulation of glucokinase gene expression in cultured
hepatocytes. Eur. J. Biochem. 1992, 210, 365–373. [CrossRef] [PubMed]
40. Bedoya, F.J.; Matschinsky, F.M.; Shimizu, T.; O’Neil, J.J.; Appel, M.C. Differential regulation of glucokinase
activity in pancreatic islets and liver of the rat. J. Biol. Chem. 1986, 261, 10760–10764. [PubMed]
41. Vandercammen, A.; Van Schaftingen, E. The mechanism by which rat liver glucokinase is inhibited by the
regulatory protein. Eur. J. Biochem. 1990, 191, 483–489. [CrossRef] [PubMed]
42. Raimondo, A.; Rees, M.G.; Gloyn, A.L. Glucokinase regulatory protein: Complexity at the crossroads of
triglyceride and glucose metabolism. Curr. Opin. Lipidol. 2015, 26, 88–95. [CrossRef] [PubMed]
43. Veiga-da-Cunha, M.; Van Schaftingen, E. Identification of fructose 6-phosphate- and fructose
1-phosphate-binding residues in the regulatory protein of glucokinase. J. Biol. Chem. 2002, 277, 8466–8473.
[CrossRef] [PubMed]
44. Van Schaftingen, E. A protein from rat liver confers to glucokinase the property of being antagonistically
regulated by fructose 6-phosphate and fructose 1-phosphate. Eur. J. Biochem. 1989, 179, 179–184. [CrossRef]
[PubMed]
45. Tappy, L.; Dussoix, P.; Iynedjian, P.; Henry, S.; Schneiter, P.; Zahnd, G.; Jequier, E.; Philippe, J. Abnormal
regulation of hepatic glucose output in maturity-onset diabetes of the young caused by a specific mutation
of the glucokinase gene. Diabetes 1997, 46, 204–208. [CrossRef] [PubMed]
46. Aiston, S.; Trinh, K.Y.; Lange, A.J.; Newgard, C.B.; Agius, L. Glucose-6-phosphatase overexpression lowers
glucose 6-phosphate and inhibits glycogen synthesis and glycolysis in hepatocytes without affecting
glucokinase translocation. Evidence against feedback inhibition of glucokinase. J. Biol. Chem. 1999, 274,
24559–24566. [CrossRef] [PubMed]
47. Roach, P.J. Glycogen and its metabolism. Curr. Mol. Med. 2002, 2, 101–120. [CrossRef] [PubMed]
48. Asipu, A.; Hayward, B.E.; O’Reilly, J.; Bonthron, D.T. Properties of normal and mutant recombinant human
ketohexokinases and implications for the pathogenesis of essential fructosuria. Diabetes 2003, 52, 2426–2432.
[CrossRef] [PubMed]
49. Bulik, S.; Holzhutter, H.G.; Berndt, N. The relative importance of kinetic mechanisms and variable enzyme
abundances for the regulation of hepatic glucose metabolism—Insights from mathematical modeling.
BMC Biol. 2016, 14, 15. [CrossRef] [PubMed]
50. Rui, L. Energy Metabolism in the Liver. Compr. Physiol. 2014, 4, 177–197. [PubMed]
51. Saltiel, A.R.; Kahn, C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001,
414, 799–806. [CrossRef] [PubMed]
52. Watford, M. Small amounts of dietary fructose dramatically increase hepatic glucose uptake through a novel
mechanism of glucokinase activation. Nutr. Rev. 2002, 60, 253–257. [PubMed]
53. Shiota, M.; Moore, M.C.; Galassetti, P.; Monohan, M.; Neal, D.W.; Shulman, G.I.; Cherrington, A.D.
Inclusion of low amounts of fructose with an intraduodenal glucose load markedly reduces postprandial
hyperglycemia and hyperinsulinemia in the conscious dog. Diabetes 2002, 51, 469–478. [CrossRef] [PubMed]
54. Agius, L. Hormonal and Metabolite Regulation of Hepatic Glucokinase. Annu. Rev. Nutr. 2016, 36, 389–415.
[CrossRef] [PubMed]
Nutrients 2017, 9, 1026 17 of 21
55. Hue, L.; Stalmans, W.; Van den Berghe, G.; Hers, H.G. Effect of fructose injection on the activity of glycogen
phopshorylase and synthetase. Stockh. R. Acad. Sci. 1973, 232, 133–137.
56. Thurston, J.H.; Jones, E.M.; Hauhart, R.E. Decrease and inhibition of liver glycogen phosphorylase after
fructose. An experimental model for the study of hereditary fructose intolerance. Diabetes 1974, 23, 597–604.
[CrossRef] [PubMed]
57. Moore, M.C.; Cherrington, A.D.; Mann, S.L.; Davis, S.N. Acute fructose administration decreases the glycemic
response to an oral glucose tolerance test in normal adults. J. Clin. Endocrinol. Metab. 2000, 85, 4515–4519.
[CrossRef] [PubMed]
58. Petersen, K.F.; Laurent, D.; Yu, C.; Cline, G.W.; Shulman, G.I. Stimulating effects of low-dose fructose on
insulin-stimulated hepatic glycogen synthesis in humans. Diabetes 2001, 50, 1263–1268. [CrossRef] [PubMed]
59. Hawkins, M.; Gabriely, I.; Wozniak, R.; Vilcu, C.; Shamoon, H.; Rossetti, L. Fructose improves the ability of
hyperglycemia per se to regulate glucose production in type 2 diabetes. Diabetes 2002, 51, 606–614. [CrossRef]
[PubMed]
60. Heacock, P.M.; Hertzler, S.R.; Wolf, B.W. Fructose prefeeding reduces the glycemic response to a
high-glycemic index, starchy food in humans. J. Nutr. 2002, 132, 2601–2604. [PubMed]
61. Sievenpiper, J.L.; Chiavaroli, L.; de Souza, R.J.; Mirrahimi, A.; Cozma, A.I.; Ha, V.; Wang, D.D.; Yu, M.E.;
Carleton, A.J.; Beyene, J.; et al. ‘Catalytic’ doses of fructose may benefit glycaemic control without harming
cardiometabolic risk factors: A small meta-analysis of randomised controlled feeding trials. Br. J. Nutr. 2012,
108, 418–423. [CrossRef] [PubMed]
62. Livesey, G.; Taylor, R. Fructose consumption and consequences for glycation, plasma triacylglycerol, and
body weight: Meta-analyses and meta-regression models of intervention studies. Am. J. Clin. Nutr. 2008, 88,
1419–1437. [PubMed]
63. Coate, K.C.; Kraft, G.; Moore, M.C.; Smith, M.S.; Ramnanan, C.; Irimia, J.M.; Roach, P.J.; Farmer, B.; Neal, D.W.;
Williams, P.; et al. Hepatic glucose uptake and disposition during short-term high-fat vs. high-fructose
feeding. Am. J. Physiol. Endocrinol. Metab. 2014, 307, E151–E160. [CrossRef] [PubMed]
64. Koo, H.Y.; Wallig, M.A.; Chung, B.H.; Nara, T.Y.; Cho, B.H.; Nakamura, M.T. Dietary fructose induces a
wide range of genes with distinct shift in carbohydrate and lipid metabolism in fed and fasted rat liver.
Biochim. Biophys. Acta 2008, 1782, 341–348. [CrossRef] [PubMed]
65. Kim, M.S.; Krawczyk, S.A.; Doridot, L.; Fowler, A.J.; Wang, J.X.; Trauger, S.A.; Noh, H.L.; Kang, H.J.;
Meissen, J.K.; Blatnik, M.; et al. ChREBP regulates fructose-induced glucose production independently of
insulin signaling. J. Clin. Investig. 2016, 126, 4372–4386. [CrossRef] [PubMed]
66. Clark, D.G.; Filsell, O.H.; Topping, D.L. Effects of fructose concentration on carbohydrate metabolism, heat
production and substrate cycling in isolated rat hepatocytes. Biochem. J. 1979, 184, 501–507. [CrossRef]
[PubMed]
67. Kurland, I.J.; Pilkis, S.J. Covalent control of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: Insights
into autoregulation of a bifunctional enzyme. Protein Sci. 1995, 4, 1023–1037. [CrossRef] [PubMed]
68. Theytaz, F.; de Giorgi, S.; Hodson, L.; Stefanoni, N.; Rey, V.; Schneiter, P.; Giusti, V.; Tappy, L. Metabolic fate
of fructose ingested with and without glucose in a mixed meal. Nutrients 2014, 6, 2632–2649. [CrossRef]
[PubMed]
69. Coss-Bu, J.A.; Sunehag, A.L.; Haymond, M.W. Contribution of galactose and fructose to glucose homeostasis.
Metabolism 2009, 58, 1050–1058. [CrossRef] [PubMed]
70. Cozma, A.I.; Sievenpiper, J.L.; de Souza, R.J.; Chiavaroli, L.; Ha, V.; Wang, D.D.; Mirrahimi, A.; Yu, M.E.;
Carleton, A.J.; Di Buono, M.; et al. Effect of fructose on glycemic control in diabetes: A systematic review
and meta-analysis of controlled feeding trials. Diabetes Care 2012, 35, 1611–1620. [CrossRef] [PubMed]
71. Evans, R.A.; Frese, M.; Romero, J.; Cunningham, J.H.; Mills, K.E. Fructose replacement of glucose or sucrose
in food or beverages lowers postprandial glucose and insulin without raising triglycerides: A systematic
review and meta-analysis. Am. J. Clin. Nutr. 2017, 106, 506–518. [CrossRef] [PubMed]
72. Welsh, G.I.; Proud, C.G. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and
phosphorylates eukaryotic initiation factor eIF-2B. Biochem. J. 1993, 294, 625–629. [CrossRef] [PubMed]
73. Agius, L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem. J. 2008, 414, 1–18.
[CrossRef] [PubMed]
Nutrients 2017, 9, 1026 18 of 21
74. Aiston, S.; Coghlan, M.P.; Agius, L. Inactivation of phosphorylase is a major component of the mechanism
by which insulin stimulates hepatic glycogen synthesis. Eur. J. Biochem. 2003, 270, 2773–2781. [CrossRef]
[PubMed]
75. Bianchi, A.; Evans, J.L.; Iverson, A.J.; Nordlund, A.C.; Watts, T.D.; Witters, L.A. Identification of an isozymic
form of acetyl-CoA carboxylase. J. Biol. Chem. 1990, 265, 1502–1509. [PubMed]
76. Smith, S. The animal fatty acid synthase: One gene, one polypeptide, seven enzymes. FASEB J. 1994, 8,
1248–1259. [PubMed]
77. Moon, Y.A.; Shah, N.A.; Mohapatra, S.; Warrington, J.A.; Horton, J.D. Identification of a mammalian long
chain fatty acyl elongase regulated by sterol regulatory element-binding proteins. J. Biol. Chem. 2001, 276,
45358–45366. [CrossRef] [PubMed]
78. Enoch, H.G.; Catala, A.; Strittmatter, P. Mechanism of rat liver microsomal stearyl-CoA desaturase. Studies
of the substrate specificity, enzyme-substrate interactions, and the function of lipid. J. Biol. Chem. 1976, 251,
5095–5103. [PubMed]
79. Yamashita, H.; Takenoshita, M.; Sakurai, M.; Bruick, R.K.; Henzel, W.J.; Shillinglaw, W.; Arnot, D.; Uyeda, K.
A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc. Natl.
Acad. Sci. USA 2001, 98, 9116–9121. [CrossRef] [PubMed]
80. Stoeckman, A.K.; Ma, L.; Towle, H.C. Mlx is the functional heteromeric partner of the carbohydrate
response element-binding protein in glucose regulation of lipogenic enzyme genes. J. Biol. Chem. 2004, 279,
15662–15669. [CrossRef] [PubMed]
81. Horton, J.D.; Bashmakov, Y.; Shimomura, I.; Shimano, H. Regulation of sterol regulatory element binding
proteins in livers of fasted and refed mice. Proc. Natl. Acad. Sci. USA 1998, 95, 5987–5992. [CrossRef]
[PubMed]
82. Foretz, M.; Guichard, C.; Ferre, P.; Foufelle, F. Sterol regulatory element binding protein-1c is a major
mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc. Natl.
Acad. Sci. USA 1999, 96, 12737–12742. [CrossRef] [PubMed]
83. Lee, A.-H.; Scapa, E.F.; Cohen, D.E.; Glimcher, L.H. Regulation of hepatic lipogenesis by the transcription
factor XBP1. Science 2008, 320, 1492–1496. [CrossRef] [PubMed]
84. Dentin, R.; Benhamed, F.; Pegorier, J.P.; Foufelle, F.; Viollet, B.; Vaulont, S.; Girard, J.; Postic, C.
Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP
nuclear protein translocation. J. Clin. Investig. 2005, 115, 2843–2854. [CrossRef] [PubMed]
85. Haas, J.T.; Miao, J.; Chanda, D.; Wang, Y.; Zhao, E.; Haas, M.E.; Hirschey, M.; Vaitheesvaran, B.; Farese, R.V., Jr.;
Kurland, I.J.; et al. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c
mRNA but not for feeding-dependent expression. Cell. Metab. 2012, 15, 873–884. [CrossRef] [PubMed]
86. Sirek, A.S.; Liu, L.; Naples, M.; Adeli, K.; Ng, D.S.; Jin, T. Insulin stimulates the expression of carbohydrate
response element binding protein (ChREBP) by attenuating the repressive effect of Pit-1, Oct-1/Oct-2, and
Unc-86 homeodomain protein octamer transcription factor-1. Endocrinology 2009, 150, 3483–3492. [CrossRef]
[PubMed]
87. Herman, M.A.; Peroni, O.D.; Villoria, J.; Schon, M.R.; Abumrad, N.A.; Bluher, M.; Klein, S.; Kahn, B.B. A
novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 2012, 484, 333–338.
[CrossRef] [PubMed]
88. Dentin, R.; Tomas-Cobos, L.; Foufelle, F.; Leopold, J.; Girard, J.; Postic, C.; Ferre, P. Glucose 6-phosphate,
rather than xylulose 5-phosphate, is required for the activation of ChREBP in response to glucose in the liver.
J. Hepatol. 2012, 56, 199–209. [CrossRef] [PubMed]
89. Arden, C.; Tudhope, S.J.; Petrie, J.L.; Al-Oanzi, Z.H.; Cullen, K.S.; Lange, A.J.; Towle, H.C.; Agius, L. Fructose
2,6-bisphosphate is essential for glucose-regulated gene transcription of glucose-6-phosphatase and other
ChREBP target genes in hepatocytes. Biochem. J. 2012, 443, 111–123. [CrossRef] [PubMed]
90. Kabashima, T.; Kawaguchi, T.; Wadzinski, B.E.; Uyeda, K. Xylulose 5-phosphate mediates glucose-induced
lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver. Proc. Natl. Acad. Sci. USA
2003, 100, 5107–5112. [CrossRef] [PubMed]
91. Iizuka, K.; Bruick, R.K.; Liang, G.; Horton, J.D.; Uyeda, K. Deficiency of carbohydrate response
element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl. Acad. Sci. USA 2004,
101, 7281–7286. [CrossRef] [PubMed]
Nutrients 2017, 9, 1026 19 of 21
92. Ferre, P.; Foufelle, F. Hepatic steatosis: A role for de novo lipogenesis and the transcription factor SREBP-1c.
Diabetes Obes. Metab. 2010, 12, 83–92. [CrossRef] [PubMed]
93. Moon, Y.A.; Liang, G.; Xie, X.; Frank-Kamenetsky, M.; Fitzgerald, K.; Koteliansky, V.; Brown, M.S.;
Goldstein, J.L.; Horton, J.D. The Scap/SREBP pathway is essential for developing diabetic fatty liver
and carbohydrate-induced hypertriglyceridemia in animals. Cell. Metab. 2012, 15, 240–246. [CrossRef]
[PubMed]
94. Kuriyama, H.; Liang, G.; Engelking, L.J.; Horton, J.D.; Goldstein, J.L.; Brown, M.S. Compensatory increase in
fatty acid synthesis in adipose tissue of mice with conditional deficiency of SCAP in liver. Cell. Metab. 2005,
1, 41–51. [CrossRef] [PubMed]
95. Glimcher, L.H.; Lee, A.-H. From Sugar to Fat: How the Transcription Factor XBP1 Regulates Hepatic
Lipogenesis. Ann. N. Y. Acad. Sci. 2009, 1173, E2–E9. [CrossRef] [PubMed]
96. Zhou, Y.; Lee, J.; Reno, C.M.; Sun, C.; Park, S.W.; Chung, J.; Lee, J.; Fisher, S.J.; White, M.F.; Biddinger, S.B.;
et al. Regulation of glucose homeostasis through a XBP-1-FoxO1 interaction. Nat. Med. 2011, 17, 356–365.
[CrossRef] [PubMed]
97. Lanaspa, M.A.; Sanchez-Lozada, L.G.; Choi, Y.J.; Cicerchi, C.; Kanbay, M.; Roncal-Jimenez, C.A.; Ishimoto, T.;
Li, N.; Marek, G.; Duranay, M.; et al. Uric acid induces hepatic steatosis by generation of mitochondrial
oxidative stress: Potential role in fructose-dependent and -independent fatty liver. J. Biol. Chem. 2012, 287,
40732–40744. [CrossRef] [PubMed]
98. Boesiger, P.; Buchli, R.; Meier, D.; Steinmann, B.; Gitzelmann, R. Changes of liver metabolite concentrations
in adults with disorders of fructose metabolism after intravenous fructose by 31P magnetic resonance
spectroscopy. Pediatr. Res. 1994, 36, 436–440. [CrossRef] [PubMed]
99. Aarsland, A.; Chinkes, D.; Wolfe, R.R. Contributions of de novo synthesis of fatty acids to
total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man.
J. Clin. Investig. 1996, 98, 2008–2017. [CrossRef] [PubMed]
100. Schwarz, J.M.; Noworolski, S.M.; Wen, M.J.; Dyachenko, A.; Prior, J.L.; Weinberg, M.E.; Herraiz, L.A.;
Tai, V.W.; Bergeron, N.; Bersot, T.P.; et al. Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis
and Liver Fat. J. Clin. Endocrinol. Metab. 2015, 100, 2434–2442. [CrossRef] [PubMed]
101. Egli, L.; Lecoultre, V.; Theytaz, F.; Campos, V.; Hodson, L.; Schneiter, P.; Mittendorfer, B.; Patterson, B.W.;
Fielding, B.A.; Gerber, P.A.; et al. Exercise prevents fructose-induced hypertriglyceridemia in healthy young
subjects. Diabetes 2013, 62, 2259–2265. [CrossRef] [PubMed]
102. Kersten, S.; Stienstra, R. The role and regulation of the peroxisome proliferator activated receptor alpha in
human liver. Biochimie 2017, 136, 75–84. [CrossRef] [PubMed]
103. Chakravarthy, M.V.; Lodhi, I.J.; Yin, L.; Malapaka, R.R.; Xu, H.E.; Turk, J.; Semenkovich, C.F. Identification of
a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 2009, 138, 476–488. [CrossRef]
[PubMed]
104. Longuet, C.; Sinclair, E.M.; Maida, A.; Baggio, L.L.; Maziarz, M.; Charron, M.J.; Drucker, D.J. The glucagon
receptor is required for the adaptive metabolic response to fasting. Cell. Metab. 2008, 8, 359–371. [CrossRef]
[PubMed]
105. Kersten, S.; Seydoux, J.; Peters, J.M.; Gonzalez, F.J.; Desvergne, B.; Wahli, W. Peroxisome proliferator-activated
receptor alpha mediates the adaptive response to fasting. J. Clin. Investig. 1999, 103, 1489–1498. [CrossRef]
[PubMed]
106. Leone, T.C.; Weinheimer, C.J.; Kelly, D.P. A critical role for the peroxisome proliferator-activated receptor
alpha (PPARalpha) in the cellular fasting response: The PPARalpha-null mouse as a model of fatty acid
oxidation disorders. Proc. Natl. Acad. Sci. USA 1999, 96, 7473–7478. [CrossRef] [PubMed]
107. Rebollo, A.; Roglans, N.; Baena, M.; Sanchez, R.M.; Merlos, M.; Alegret, M.; Laguna, J.C. Liquid fructose
downregulates Sirt1 expression and activity and impairs the oxidation of fatty acids in rat and human liver
cells. Biochim. Biophys. Acta 2014, 1841, 514–524. [CrossRef] [PubMed]
108. Sanderson, L.M.; de Groot, P.J.; Hooiveld, G.J.; Koppen, A.; Kalkhoven, E.; Muller, M.; Kersten, S. Effect
of synthetic dietary triglycerides: A novel research paradigm for nutrigenomics. PLoS ONE 2008, 3, e1681.
[CrossRef] [PubMed]
109. McGarry, J.D.; Brown, N.F. The mitochondrial carnitine palmitoyltransferase system. From concept to
molecular analysis. Eur. J. Biochem. 1997, 244, 1–14. [CrossRef] [PubMed]
Nutrients 2017, 9, 1026 20 of 21
110. Foster, D.W. Malonyl-CoA: The regulator of fatty acid synthesis and oxidation. J. Clin. Investig. 2012, 122,
1958–1959. [CrossRef] [PubMed]
111. McGarry, J.D.; Mannaerts, G.P.; Foster, D.W. A possible role for malonyl-CoA in the regulation of hepatic
fatty acid oxidation and ketogenesis. J. Clin. Investig. 1977, 60, 265–270. [CrossRef] [PubMed]
112. McGarry, J.D.; Leatherman, G.F.; Foster, D.W. Carnitine palmitoyltransferase I. The site of inhibition of
hepatic fatty acid oxidation by malonyl-CoA. J. Biol. Chem. 1978, 253, 4128–4136. [PubMed]
113. Koutsari, C.; Sidossis, L.S. Effect of isoenergetic low- and high-carbohydrate diets on substrate kinetics and
oxidation in healthy men. Br. J. Nutr. 2003, 90, 413–418. [CrossRef] [PubMed]
114. Sidossis, L.S.; Stuart, C.A.; Shulman, G.I.; Lopaschuk, G.D.; Wolfe, R.R. Glucose plus insulin regulate fat
oxidation by controlling the rate of fatty acid entry into the mitochondria. J. Clin. Investig. 1996, 98, 2244–2250.
[CrossRef] [PubMed]
115. Vatner, D.F.; Majumdar, S.K.; Kumashiro, N.; Petersen, M.C.; Rahimi, Y.; Gattu, A.K.; Bears, M.; Camporez, J.P.;
Cline, G.W.; Jurczak, M.J.; et al. Insulin-independent regulation of hepatic triglyceride synthesis by fatty
acids. Proc. Natl. Acad. Sci. USA 2015, 112, 1143–1148. [CrossRef] [PubMed]
116. Aarsland, A.; Wolfe, R.R. Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men.
J. Lipid Res. 1998, 39, 1280–1286. [PubMed]
117. Hodson, L.; Frayn, K.N. Hepatic fatty acid partitioning. Curr. Opin. Lipidol. 2011, 22, 216–224. [CrossRef]
[PubMed]
118. Barrows, B.R.; Parks, E.J. Contributions of different fatty acid sources to very low-density
lipoprotein-triacylglycerol in the fasted and fed states. J. Clin. Endocrinol. Metab. 2006, 91, 1446–1452.
[CrossRef] [PubMed]
119. Nelson, R.H.; Basu, R.; Johnson, C.M.; Rizza, R.A.; Miles, J.M. Splanchnic spillover of extracellular
lipase-generated fatty acids in overweight and obese humans. Diabetes 2007, 56, 2878–2884. [CrossRef]
[PubMed]
120. Bradbury, M.W. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: Possible role in
steatosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290, G194–G198. [CrossRef] [PubMed]
121. Ginsberg, H.N.; Fisher, E.A. The ever-expanding role of degradation in the regulation of apolipoprotein B
metabolism. J. Lipid Res. 2009, 50, S162–S166. [CrossRef] [PubMed]
122. Mittendorfer, B.; Sidossis, L.S. Mechanism for the increase in plasma triacylglycerol concentrations after
consumption of short-term, high-carbohydrate diets. Am. J. Clin. Nutr. 2001, 73, 892–899. [PubMed]
123. Bantle, J.P.; Raatz, S.K.; Thomas, W.; Georgopoulos, A. Effects of dietary fructose on plasma lipids in healthy
subjects. Am. J. Clin. Nutr. 2000, 72, 1128–1134. [PubMed]
124. Parks, E.J.; Skokan, L.E.; Timlin, M.T.; Dingfelder, C.S. Dietary sugars stimulate fatty acid synthesis in adults.
J. Nutr. 2008, 138, 1039–1046. [PubMed]
125. Hochuli, M.; Aeberli, I.; Weiss, A.; Hersberger, M.; Troxler, H.; Gerber, P.A.; Spinas, G.A.; Berneis, K.
Sugar-sweetened beverages with moderate amounts of fructose, but not sucrose, induce Fatty Acid synthesis
in healthy young men: A randomized crossover study. J. Clin. Endocrinol. Metab. 2014, 99, 2164–2172.
[CrossRef] [PubMed]
126. Chong, M.F.; Fielding, B.A.; Frayn, K.N. Mechanisms for the acute effect of fructose on postprandial lipemia.
Am. J. Clin. Nutr. 2007, 85, 1511–1520. [PubMed]
127. Chiavaroli, L.; de Souza, R.J.; Ha, V.; Cozma, A.I.; Mirrahimi, A.; Wang, D.D.; Yu, M.; Carleton, A.J.; Di
Buono, M.; Jenkins, A.L.; et al. Effect of Fructose on Established Lipid Targets: A Systematic Review and
Meta-Analysis of Controlled Feeding Trials. J. Am. Heart Assoc. 2015, 4, e001700. [CrossRef] [PubMed]
128. Wang, D.; Sievenpiper, J.L.; de Souza, R.J.; Cozma, A.I.; Chiavaroli, L.; Ha, V.; Mirrahimi, A.; Carleton, A.J.;
Di Buono, M.; Jenkins, A.L.; et al. Effect of fructose on postprandial triglycerides: A systematic review and
meta-analysis of controlled feeding trials. Atherosclerosis 2014, 232, 125–133. [CrossRef] [PubMed]
129. Sievenpiper, J.L.; Carleton, A.J.; Chatha, S.; Jiang, H.Y.; de Souza, R.J.; Beyene, J.; Kendall, C.W.; Jenkins, D.J.
Heterogeneous effects of fructose on blood lipids in individuals with type 2 diabetes: Systematic review and
meta-analysis of experimental trials in humans. Diabetes Care 2009, 32, 1930–1937. [CrossRef] [PubMed]
130. Chiu, S.; Sievenpiper, J.L.; de Souza, R.J.; Cozma, A.I.; Mirrahimi, A.; Carleton, A.J.; Ha, V.; Di Buono, M.;
Jenkins, A.L.; Leiter, L.A.; et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD):
A systematic review and meta-analysis of controlled feeding trials. Eur. J. Clin. Nutr. 2014, 68, 416–423.
[CrossRef] [PubMed]
Nutrients 2017, 9, 1026 21 of 21
131. Ter Horst, K.W.; Schene, M.R.; Holman, R.; Romijn, J.A.; Serlie, M.J. Effect of fructose consumption on insulin
sensitivity in nondiabetic subjects: A systematic review and meta-analysis of diet-intervention trials. Am. J.
Clin. Nutr. 2016, 104, 1562–1576. [CrossRef] [PubMed]
132. Stanhope, K.L.; Schwarz, J.M.; Keim, N.L.; Griffen, S.C.; Bremer, A.A.; Graham, J.L.; Hatcher, B.; Cox, C.L.;
Dyachenko, A.; Zhang, W.; et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases
visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J. Clin. Investig.
2009, 119, 1322–1334. [CrossRef] [PubMed]
133. Aeberli, I.; Hochuli, M.; Gerber, P.A.; Sze, L.; Murer, S.B.; Tappy, L.; Spinas, G.A.; Berneis, K. Moderate
amounts of fructose consumption impair insulin sensitivity in healthy young men: A randomized controlled
trial. Diabetes Care 2013, 36, 150–156. [CrossRef] [PubMed]
134. Patel, C.; Sugimoto, K.; Douard, V.; Shah, A.; Inui, H.; Yamanouchi, T.; Ferraris, R.P. Effect of dietary fructose
on portal and systemic serum fructose levels in rats and in KHK-/- and GLUT5-/-mice. Am. J. Physiol.
Gastrointest. Liver Physiol. 2015, 309, G779–G790. [CrossRef] [PubMed]
135. Baena, M.; Sangüesa, G.; Dávalos, A.; Latasa, M.-J.; Sala-Vila, A.; Sánchez, R.M.; Roglans, N.; Laguna, J.C.;
Alegret, M. Fructose, but not glucose, impairs insulin signaling in the three major insulin-sensitive tissues.
Sci. Rep. 2016, 6, 26149. [CrossRef] [PubMed]
136. Kinote, A.; Faria, J.A.; Roman, E.A.; Solon, C.; Razolli, D.S.; Ignacio-Souza, L.M.; Sollon, C.S.; Nascimento, L.F.;
de Araujo, T.M.; Barbosa, A.P.; et al. Fructose-induced hypothalamic AMPK activation stimulates hepatic
PEPCK and gluconeogenesis due to increased corticosterone levels. Endocrinology 2012, 153, 3633–3645.
[CrossRef] [PubMed]
137. Samuel, V.T.; Liu, Z.X.; Qu, X.; Elder, B.D.; Bilz, S.; Befroy, D.; Romanelli, A.J.; Shulman, G.I. Mechanism of
hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 2004, 279, 32345–32353. [CrossRef]
[PubMed]
138. Jurczak, M.J.; Lee, A.H.; Jornayvaz, F.R.; Lee, H.Y.; Birkenfeld, A.L.; Guigni, B.A.; Kahn, M.; Samuel, V.T.;
Glimcher, L.H.; Shulman, G.I. Dissociation of inositol-requiring enzyme (IRE1alpha)-mediated c-Jun
N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1)
knock-out mice. J. Biol. Chem. 2012, 287, 2558–2567. [CrossRef] [PubMed]
139. Evans, R.A.; Frese, M.; Romero, J.; Cunningham, J.H.; Mills, K.E. Chronic fructose substitution for glucose or
sucrose in food or beverages has little effect on fasting blood glucose, insulin, or triglycerides: A systematic
review and meta-analysis. Am. J. Clin. Nutr. 2017, 106, 519–529. [CrossRef] [PubMed]
140. Sievenpiper, J.L.; de Souza, R.J.; Mirrahimi, A.; Yu, M.E.; Carleton, A.J.; Beyene, J.; Chiavaroli, L.; Di
Buono, M.; Jenkins, A.L.; Leiter, L.A.; et al. Effect of fructose on body weight in controlled feeding trials:
A systematic review and meta-analysis. Ann. Intern. Med. 2012, 156, 291–304. [CrossRef] [PubMed]
141. Ha, V.; Sievenpiper, J.L.; de Souza, R.J.; Chiavaroli, L.; Wang, D.D.; Cozma, A.I.; Mirrahimi, A.; Yu, M.E.;
Carleton, A.J.; Dibuono, M.; et al. Effect of fructose on blood pressure: A systematic review and meta-analysis
of controlled feeding trials. Hypertension 2012, 59, 787–795. [CrossRef] [PubMed]
142. Wang, D.D.; Sievenpiper, J.L.; de Souza, R.J.; Chiavaroli, L.; Ha, V.; Cozma, A.I.; Mirrahimi, A.; Yu, M.E.;
Carleton, A.J.; Di Buono, M.; et al. The effects of fructose intake on serum uric acid vary among controlled
dietary trials. J. Nutr. 2012, 142, 916–923. [CrossRef] [PubMed]
143. Sievenpiper, J.L.; de Souza, R.J.; Cozma, A.I.; Chiavaroli, L.; Ha, V.; Mirrahimi, A. Fructose vs. glucose and
metabolism: Do the metabolic differences matter? Curr. Opin. Lipidol. 2014, 25, 8–19. [CrossRef] [PubMed]
144. Nagai, Y.; Yonemitsu, S.; Erion, D.M.; Iwasaki, T.; Stark, R.; Weismann, D.; Dong, J.; Zhang, D.; Jurczak, M.J.;
Loffler, M.G.; et al. The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the
pathogenesis of fructose-induced insulin resistance. Cell. Metab. 2009, 9, 252–264. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
